Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924785 | 1.00 | CYP3A4 (0.36) | CYP3A4CYP2D6CYP2C19SMN1; SMN2DPP7 | |
| SCHEMBL15955649 | 1.00 | CYP3A4 (0.36) | CYP3A4CYP2D6CYP2C19SMN1; SMN2DPP7 | |
| SCHEMBL17331178 | 1.00 | CYP3A4 (0.36) | CYP3A4CYP2D6CYP2C19SMN1; SMN2DPP7 | |
| SCHEMBL12714695 | 0.97 | — | — | |
| SCHEMBL1613076 | 0.97 | — | — | |
| SCHEMBL1613074 | 0.97 | — | — | |
| SCHEMBL11224155 | 0.86 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL21096753 | 0.86 | — | — | |
| SCHEMBL27565285 | 0.80 | CYP3A4 (0.39) | CYP3A4CYP2D6CYP2C19SMN1; SMN2DPP7 | |
| SCHEMBL3817000 | 0.80 | DPP7 (0.35) | CYP3A4CYP2D6CYP2C19SMN1; SMN2DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202799-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-9884063-B2 | Amido-substituted azole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| EP-3126337-A2 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-02-08 | — | — | EP | disclosed |
| US-20170020886-A1 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150449-A2 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| EP-2207801-B1 | METHODS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8207209-B2 | Methods of inhibiting viral infection | FUNCTIONAL GENETICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2346856-A1 | 2-[1H-BENZIMIDAZOL-2(3H)-YLIDENE]-2-(PYRIMIDIN-2-YL)ACETAMIDES AND 2-[BENZOTHIAZOL-2(3H)-YLIDENE]-2-(PYRIMIDIN-2-YL)ACETAMIDES AS KINASE INHIBITORS | Telik, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2207801-A1 | METHODS OF INHIBITING VIRAL INFECTION | Functional Genetics, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2010036873-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1311507-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016359-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| EP-0821594-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1998-02-04 | — | — | EP | disclosed |
| US-4525356-A | UROGENITAL DISORDERS | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1985-06-25 | — | — | US | disclosed |
| EP-0108986-A1 | N-substituted flavone-8-carboxamides | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1984-05-23 | — | — | EP | disclosed |
| US-4145347-A | TREATMENT OF SENILITY, AMNESIA AND LEARNING DISORDERS | PARKE, DAVIS & COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
| US-3993694-A | BACTERICIDE | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-11-23 | — | — | US | disclosed |
| US-3983173-A | ANTIBIOTIC | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | CYP3A4 601/4885CYP2D6 580/4885CYP2C19 193/4885 |
| US-20190202799-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | BRD4, BRPF3, BRD3 | CYP3A4 2346/4885CYP2D6 4268/4885CYP2C19 3746/4885 |
| US-20170020886-A1 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | TNK1, TNNI3K, TNKS | CYP3A4 698/4885CYP2D6 954/4885CYP2C19 222/4885 |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | CYP3A4 1454/4885CYP2D6 2734/4885CYP2C19 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.